<DOC>
	<DOCNO>NCT03051841</DOCNO>
	<brief_summary>This study determine maximum tolerate dose ( MTD ) , dose limit toxicity ( DLT ) , safety pharmacokinetics ( PK ) profile single agent CKD-581 injection Combination Bortezomib Dexamethasone patient Previously Treated Multiple Myeloma .</brief_summary>
	<brief_title>CKD-581 + Bortezomib + Dexamethasone Patients With Previously Treated Multiple Myeloma</brief_title>
	<detailed_description>This open label , dose escalation study . Cohort 3~6 patient receive escalation dose CKD-516 maximum toleated dose ( MTD ) determine . The MTD defiend dose precede 2 3 2 6 patient experience dose limit toxicity .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>must receive least two prior line therapy Diagnosis symptomatic multiple myeloma ( IMWG 2015 ) Eastern Cooperative Oncology Group performance status ≤ 2 Life expectancy 12 week must follow laboratory value within 3 week prior first dose study drug ANC ( absolute neutrophil count ) ≥ 1,500 mm3 PLT ( platelet count ) ≥ 100,000 mm3 Hb ≥ 9.0g/dL Corrected serum calcium ≤ 11.5mg/dL AST ( SGOT ) ALT ( SGPT ) ≤ 3 x UNL ( upper limit normal ) Serum bilirubin ≤ 1.5 x ULN ( , Gilbert syndrome ≤ 3 x UNL ) Serum Cr ≤ 1.5 x UNL One measureable disease follow value Serum Mprotein ≥ 1g/dL Urine MProtein ≥ 200mg/24hr case serum Mprotein , urine MProtein nonmeasurable FLC ratio abnormal , Serum FLC level ≥ 100mg/L ( ≥10mg/dL ) 24 week prior last bortezomib dose must sign consent form Patients central neurological disease Patients clinically significant heart disease within 24weeks prior first dose study drug patient clinically significans abnormal EKG , echocardiography screen patient active hepatitis , HIV positive ( exception , non active hepatitis ) peripheral neuropathy ≥ CTCAE grade 2 peripheral neuropathy ≥ CTCAE grade 1 pain within 2 week prior first dose study drug Patients clinically significant pulmonary disease Patients prior malignancy last 5 year except adequately treat basal cell squamous cell skin cancer , situ cervical cancer Patients receive surgery , chemotherapy , radiation therapy immunotherapy investigational drug ≤ 4 week prior first dose study drug treatment period Women pregnant breast feed woman childbearing potential use effective method birth control . Male patient whose sexual partner use effective birth control . patient hypersensitive reaction bortezomib dexamethasone patient without best overall response minimal response base IMWG 2015 past treatment multiple myeloma patient refractory past bortezomib treatment ( ex ; minimal response ) progress within 60days prior last bortezomib treatment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>